Protein kinases are important regulators of intracellular signal transduction pathways. Although their activities are tightly controlled and regulated under normal conditions, perturbation by mutations or other genetic alterations results in deregulated kinase activity and malignant transformation. Even though a few tyrosine kinase genes have been shown to be mutated in specific human cancers, it is unknown how many or how often members of the tyrosine kinase gene family are altered in any particular cancer type (Blume-Jensen and Hunter, 2001) . A recent study by Bardelli et al. (2003) that involved comprehensive mutational analysis of 138 tyrosine kinases from colorectal cancer cells found seven genes with substantial mutations in more than one cell. To expand on these results, we examined 33 sites in these seven tyrosine kinase genes (NTRK3, FES, KDR, EPHA3, NTRK2, MLK4 and GUCY2F) in eight human hepatic, seven human pancreatic and seven human gastric cancer cell lines to look for the mutations found in colorectal cancers. However, no mutations were observed in the hepatic, pancreatic and gastric cancer cell lines (Shao et al., 2005) .
To further explore these mutations, we examined all mutations of NTRK3, FES, KDR, EPHA3, NTRK2, JAK1, PDGFRA, EPHA7, EPHA8, ERBB4, FGFR1, MLK4 and GUCY2F genes reported by Bardelli et al. (2003) except one mutation of INSRR gene (because this gene was not found in the NCBI Genbank) in the 24 colorectal cancer cell lines and 46 colorectal cancer samples from Japanese patients. Human colon cancer cell lines (HCT116, CaCo2, DLD1, SW620, LoVo, Colo320, CaR1, LS174T, RCM1, SW48, SW837, WiDr, HCT15, HT29, SW984, SW480, SNU-C, SW403, LS180, RKO, Colo210, Colo205, RKO-E6 and T84) were obtained from the Riken cell bank (Tsukuba Science City, Japan). Genomic DNA was extracted from cells using a SepaGene DNA extraction kit (Sanko Junyaku, Tokyo, Japan) according to the manufacturer's instructions. Forty-six resection specimens were brought fresh from theater to pathology. Normal and tumor tissue samples were selected by an experienced pathologist and stored in liquid nitrogen before analysis. The background data on the 46 patients with colorectal cancer was summarized in the Table 1 . Genomic DNA of tissue samples was extracted using a QIAamp DNA Mini Kit (QIAGEN, Hilden, Germany) according to the manufacturer's instructions. This study was performed with appropriate Institutional Review Board approval.
The polymerase chain reaction (PCR) and synthesis of the DNA-sequencing primers were performed as previously reported (Bardelli et al., 2003) . New PCR and DNA-sequencing primers were designed for three mutations in MLK4 (C1657T, A1787T and A1885G), one mutation in PDGFRA and one mutation in FGFR1, because these primers were not shown in the previous report. Primers are shown in Table 2 . Using these new primers for sequencing, we were able to obtain clear information about mutations in these genes. We also selected PIK3CA (exons 9 and 20), K-ras (codons 12 and 13) and B-raf (exon 15) for mutation analysis of the same 46 colon cancer tissue samples. PCR and DNA sequencing for PIK3CA mutation were performed as previously reported (Samuels et al., 2004) . PCR and DNA-sequencing primers for K-ras and B-raf mutations are shown in Table 2 . PCR was performed in 50-ml reaction mixtures containing 0.25 mM dNTPs, 1 mM each of the forward and reverse primers, 6% dimethylsulfoxide (DMSO), 1 Â PCR buffer, 25 ng DNA and 2.5 U platinum Taq (Invitrogen, Carlsbad, CA, USA In these experiments, among 24 colorectal cancer cell lines, only two cell lines (LoVo and CaR1) harbored mutation C1408T (R470C) in MLK4 gene. The mutation rate was extremely low compared to that reported by Bardelli et al. (2003) ; therefore, we analyzed mutations in 46 colorectal cancer samples resected from the same number of Japanese patients. Surprisingly, none of the 46 samples contained any of the mutations reported by Bardelli et al. (2003) . Bardelli et al. reported that a minimum of 30% of colorectal cancer contain at least one mutation in the tyrosine kinases. Although we sequenced totally about 12.7 kilobases of tyrosine kinases in one sample, we could find no nonsynonymous mutations. Primary tumors always contain nonneoplastic cells, and thus, it is possible that presumptive mutations can be masked or difficult to interpret. To ascertain the influence of this factor in the present study, we examined mutations in PIK3CA (exons 9 and 20), K-ras (codons 12 and 13), and B-raf (exon 15) genes in parallel. The mutation rates were 13.0% (6/46), 23.9% (11/46) and 8.7% (4/46), respectively. These rates were close to those previously reported (B13.6, 27.4 and 9.1%, respectively) in European colorectal cancer cases (Davies et al., 2002; Smith et al., 2002; Velho et al., 2005) . These results indicate that detection of mutations by our method was not appreciably influenced by contamination with non-neoplastic cells. In this study, we showed that there were no tyrosine kinase mutations in human colorectal cancer samples from Japanese patients. This differs markedly from the findings of Bardelli et al. (2003) . There were very few recurrent mutations in the genes reported by Bardelli et al. in our data. It is possible that the genes examined have other mutations in other exons that this study would not have identified. We note that Bardelli et al. (2003) used early-passage colorectal cancer cell lines or samples of xenografts in nude mice. It is possible that these methods may increase artificial mutations, which were produced in the course of passage or xenografting in nude mice. It is also possible that these methods select more malignant tumor cells. Moreover, it is possible that either the majority of mutations reported by Bardelli et al. are passenger mutations (not oncogenic) or there is a great degree of diversity of tyrosine kinase mutations that can play a role in colorectal cancer. Based on our study, we advise that a more comprehensive tyrosine kinase gene mutation assay is necessary in the future.
